These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 30258217)

  • 1. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
    Bar-On Y; Gruell H; Schoofs T; Pai JA; Nogueira L; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Karagounis T; Cohen YZ; Wyen C; Scholten S; Handl L; Belblidia S; Dizon JP; Vehreschild JJ; Witmer-Pack M; Shimeliovich I; Jain K; Fiddike K; Seaton KE; Yates NL; Horowitz J; Gulick RM; Pfeifer N; Tomaras GD; Seaman MS; Fätkenheuer G; Caskey M; Klein F; Nussenzweig MC
    Nat Med; 2018 Nov; 24(11):1701-1707. PubMed ID: 30258217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.
    Caskey M; Klein F; Lorenzi JC; Seaman MS; West AP; Buckley N; Kremer G; Nogueira L; Braunschweig M; Scheid JF; Horwitz JA; Shimeliovich I; Ben-Avraham S; Witmer-Pack M; Platten M; Lehmann C; Burke LA; Hawthorne T; Gorelick RJ; Walker BD; Keler T; Gulick RM; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC
    Nature; 2015 Jun; 522(7557):487-91. PubMed ID: 25855300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination anti-HIV antibodies provide sustained virological suppression.
    Sneller MC; Blazkova J; Justement JS; Shi V; Kennedy BD; Gittens K; Tolstenko J; McCormack G; Whitehead EJ; Schneck RF; Proschan MA; Benko E; Kovacs C; Oguz C; Seaman MS; Caskey M; Nussenzweig MC; Fauci AS; Moir S; Chun TW
    Nature; 2022 Jun; 606(7913):375-381. PubMed ID: 35650437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
    Mendoza P; Gruell H; Nogueira L; Pai JA; Butler AL; Millard K; Lehmann C; Suárez I; Oliveira TY; Lorenzi JCC; Cohen YZ; Wyen C; Kümmerle T; Karagounis T; Lu CL; Handl L; Unson-O'Brien C; Patel R; Ruping C; Schlotz M; Witmer-Pack M; Shimeliovich I; Kremer G; Thomas E; Seaton KE; Horowitz J; West AP; Bjorkman PJ; Tomaras GD; Gulick RM; Pfeifer N; Fätkenheuer G; Seaman MS; Klein F; Caskey M; Nussenzweig MC
    Nature; 2018 Sep; 561(7724):479-484. PubMed ID: 30258136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
    Julg B; Stephenson KE; Wagh K; Tan SC; Zash R; Walsh S; Ansel J; Kanjilal D; Nkolola J; Walker-Sperling VEK; Ophel J; Yanosick K; Borducchi EN; Maxfield L; Abbink P; Peter L; Yates NL; Wesley MS; Hassell T; Gelderblom HC; deCamp A; Mayer BT; Sato A; Gerber MW; Giorgi EE; Gama L; Koup RA; Mascola JR; Monczor A; Lupo S; Rolle CP; Arduino R; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
    Nat Med; 2022 Jun; 28(6):1288-1296. PubMed ID: 35551291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection.
    Lynch RM; Boritz E; Coates EE; DeZure A; Madden P; Costner P; Enama ME; Plummer S; Holman L; Hendel CS; Gordon I; Casazza J; Conan-Cibotti M; Migueles SA; Tressler R; Bailer RT; McDermott A; Narpala S; O'Dell S; Wolf G; Lifson JD; Freemire BA; Gorelick RJ; Pandey JP; Mohan S; Chomont N; Fromentin R; Chun TW; Fauci AS; Schwartz RM; Koup RA; Douek DC; Hu Z; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    Sci Transl Med; 2015 Dec; 7(319):319ra206. PubMed ID: 26702094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
    Stephenson KE; Julg B; Tan CS; Zash R; Walsh SR; Rolle CP; Monczor AN; Lupo S; Gelderblom HC; Ansel JL; Kanjilal DG; Maxfield LF; Nkolola J; Borducchi EN; Abbink P; Liu J; Peter L; Chandrashekar A; Nityanandam R; Lin Z; Setaro A; Sapiente J; Chen Z; Sunner L; Cassidy T; Bennett C; Sato A; Mayer B; Perelson AS; deCamp A; Priddy FH; Wagh K; Giorgi EE; Yates NL; Arduino RC; DeJesus E; Tomaras GD; Seaman MS; Korber B; Barouch DH
    Nat Med; 2021 Oct; 27(10):1718-1724. PubMed ID: 34621054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.
    Caskey M; Schoofs T; Gruell H; Settler A; Karagounis T; Kreider EF; Murrell B; Pfeifer N; Nogueira L; Oliveira TY; Learn GH; Cohen YZ; Lehmann C; Gillor D; Shimeliovich I; Unson-O'Brien C; Weiland D; Robles A; Kümmerle T; Wyen C; Levin R; Witmer-Pack M; Eren K; Ignacio C; Kiss S; West AP; Mouquet H; Zingman BS; Gulick RM; Keler T; Bjorkman PJ; Seaman MS; Hahn BH; Fätkenheuer G; Schlesinger SJ; Nussenzweig MC; Klein F
    Nat Med; 2017 Feb; 23(2):185-191. PubMed ID: 28092665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.
    Scheid JF; Horwitz JA; Bar-On Y; Kreider EF; Lu CL; Lorenzi JC; Feldmann A; Braunschweig M; Nogueira L; Oliveira T; Shimeliovich I; Patel R; Burke L; Cohen YZ; Hadrigan S; Settler A; Witmer-Pack M; West AP; Juelg B; Keler T; Hawthorne T; Zingman B; Gulick RM; Pfeifer N; Learn GH; Seaman MS; Bjorkman PJ; Klein F; Schlesinger SJ; Walker BD; Hahn BH; Nussenzweig MC; Caskey M
    Nature; 2016 Jul; 535(7613):556-60. PubMed ID: 27338952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice.
    Horwitz JA; Halper-Stromberg A; Mouquet H; Gitlin AD; Tretiakova A; Eisenreich TR; Malbec M; Gravemann S; Billerbeck E; Dorner M; Büning H; Schwartz O; Knops E; Kaiser R; Seaman MS; Wilson JM; Rice CM; Ploss A; Bjorkman PJ; Klein F; Nussenzweig MC
    Proc Natl Acad Sci U S A; 2013 Oct; 110(41):16538-43. PubMed ID: 24043801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.
    Nishimura Y; Martin MA
    Cell Host Microbe; 2017 Aug; 22(2):207-216. PubMed ID: 28799906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.
    Schoofs T; Klein F; Braunschweig M; Kreider EF; Feldmann A; Nogueira L; Oliveira T; Lorenzi JC; Parrish EH; Learn GH; West AP; Bjorkman PJ; Schlesinger SJ; Seaman MS; Czartoski J; McElrath MJ; Pfeifer N; Hahn BH; Caskey M; Nussenzweig MC
    Science; 2016 May; 352(6288):997-1001. PubMed ID: 27199429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.
    Medina-Ramírez M; Sánchez-Merino V; Sánchez-Palomino S; Merino-Mansilla A; Ferreira CB; Pérez I; González N; Alvarez A; Alcocer-González JM; García F; Gatell JM; Alcamí J; Yuste E
    J Virol; 2011 Jun; 85(12):5804-13. PubMed ID: 21471239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
    Cohen YZ; Caskey M
    Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
    Bar KJ; Sneller MC; Harrison LJ; Justement JS; Overton ET; Petrone ME; Salantes DB; Seamon CA; Scheinfeld B; Kwan RW; Learn GH; Proschan MA; Kreider EF; Blazkova J; Bardsley M; Refsland EW; Messer M; Clarridge KE; Tustin NB; Madden PJ; Oden K; O'Dell SJ; Jarocki B; Shiakolas AR; Tressler RL; Doria-Rose NA; Bailer RT; Ledgerwood JE; Capparelli EV; Lynch RM; Graham BS; Moir S; Koup RA; Mascola JR; Hoxie JA; Fauci AS; Tebas P; Chun TW
    N Engl J Med; 2016 Nov; 375(21):2037-2050. PubMed ID: 27959728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.
    Freund NT; Wang H; Scharf L; Nogueira L; Horwitz JA; Bar-On Y; Golijanin J; Sievers SA; Sok D; Cai H; Cesar Lorenzi JC; Halper-Stromberg A; Toth I; Piechocka-Trocha A; Gristick HB; van Gils MJ; Sanders RW; Wang LX; Seaman MS; Burton DR; Gazumyan A; Walker BD; West AP; Bjorkman PJ; Nussenzweig MC
    Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
    Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Focus on the therapeutic efficacy of 3BNC117 against HIV-1: In vitro studies, in vivo studies, clinical trials and challenges.
    Liu ZJ; Bai J; Liu FL; Zhang XY; Wang JZ
    Int Immunopharmacol; 2017 Nov; 52():44-50. PubMed ID: 28858725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated prevention and treatment of HIV-1 infection.
    Gruell H; Klein F
    Retrovirology; 2018 Nov; 15(1):73. PubMed ID: 30445968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.